Sirolimus: Comparison of different sirolimus discontinuation strategies.
Study summary
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.
* With evaluable clinical or imaging parameters to monitor disease activity or recurrence.
* Patients or their guardians are able to understand the study and provide written informed consent.
* Hematologic and hepatic/renal function meet the safety criteria for drug administration.
Exclusion Criteria:
* Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.
Primary outcome measure(s)
Rebound growth rate of KHE — 12 months The primary endpoint is the rebound growth rate of KHE during the follow-up period.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.